-DOCSTART- -X- O
BACKGROUND -X- _ O
: -X- _ O
In -X- _ O
endemic -X- _ O
areas -X- _ O
, -X- _ O
pregnant -X- _ B-Patient
women -X- _ I-Patient
are -X- _ O
highly -X- _ O
susceptible -X- _ O
to -X- _ O
Plasmodium -X- _ B-Intervention
falciparum -X- _ I-Intervention
malaria -X- _ I-Intervention
characterized -X- _ O
by -X- _ O
the -X- _ O
accumulation -X- _ O
of -X- _ O
parasitized -X- _ O
red -X- _ O
blood -X- _ O
cells -X- _ O
( -X- _ O
pRBC -X- _ O
) -X- _ O
in -X- _ O
the -X- _ O
placenta. -X- _ O
In -X- _ O
subsequent -X- _ O
pregnancies -X- _ O
, -X- _ O
women -X- _ O
develop -X- _ O
protective -X- _ O
immunity -X- _ O
to -X- _ O
pregnancy-associated -X- _ O
malaria -X- _ O
and -X- _ O
this -X- _ O
has -X- _ O
been -X- _ O
hypothesized -X- _ O
to -X- _ O
be -X- _ O
due -X- _ O
to -X- _ O
the -X- _ O
acquisition -X- _ O
of -X- _ O
antibodies -X- _ O
to -X- _ O
the -X- _ O
parasite -X- _ O
variant -X- _ O
surface -X- _ O
antigen -X- _ O
VAR2CSA. -X- _ O
In -X- _ O
this -X- _ O
systematic -X- _ O
review -X- _ O
we -X- _ O
provide -X- _ O
the -X- _ O
first -X- _ O
synthesis -X- _ O
of -X- _ O
the -X- _ O
association -X- _ O
between -X- _ O
antibodies -X- _ O
to -X- _ O
pregnancy-specific -X- _ O
P. -X- _ O
falciparum -X- _ O
antigens -X- _ O
and -X- _ O
pregnancy -X- _ O
and -X- _ O
birth -X- _ O
outcomes. -X- _ O
METHODS -X- _ O
: -X- _ O
We -X- _ O
conducted -X- _ O
a -X- _ O
systematic -X- _ O
review -X- _ O
and -X- _ O
meta-analysis -X- _ O
of -X- _ O
population-based -X- _ O
studies -X- _ O
( -X- _ O
published -X- _ O
up -X- _ O
to -X- _ O
07 -X- _ O
June -X- _ O
2019 -X- _ O
) -X- _ O
of -X- _ O
pregnant -X- _ B-Patient
women -X- _ I-Patient
living -X- _ O
in -X- _ O
P. -X- _ O
falciparum -X- _ O
endemic -X- _ O
areas -X- _ O
that -X- _ O
examined -X- _ O
antibody -X- _ O
responses -X- _ O
to -X- _ O
pregnancy-specific -X- _ O
P. -X- _ O
falciparum -X- _ O
antigens -X- _ O
and -X- _ O
outcomes -X- _ O
including -X- _ O
placental -X- _ O
malaria -X- _ O
, -X- _ O
low -X- _ O
birthweight -X- _ O
, -X- _ O
preterm -X- _ O
birth -X- _ O
, -X- _ O
peripheral -X- _ O
parasitaemia -X- _ O
, -X- _ O
maternal -X- _ O
anaemia -X- _ O
, -X- _ O
and -X- _ O
severe -X- _ O
malaria. -X- _ O
RESULTS -X- _ O
: -X- _ O
We -X- _ O
searched -X- _ O
6 -X- _ O
databases -X- _ O
and -X- _ O
identified -X- _ O
33 -X- _ O
studies -X- _ O
( -X- _ O
30 -X- _ O
from -X- _ O
Africa -X- _ O
) -X- _ O
that -X- _ O
met -X- _ O
predetermined -X- _ O
inclusion -X- _ O
and -X- _ O
quality -X- _ O
criteria -X- _ O
: -X- _ O
16 -X- _ O
studies -X- _ O
contributed -X- _ O
estimates -X- _ O
in -X- _ O
a -X- _ O
format -X- _ O
enabling -X- _ O
inclusion -X- _ O
in -X- _ O
meta-analysis -X- _ O
and -X- _ O
17 -X- _ O
were -X- _ O
included -X- _ O
in -X- _ O
narrative -X- _ O
form -X- _ O
only. -X- _ O
Estimates -X- _ O
were -X- _ O
mostly -X- _ O
from -X- _ O
cross-sectional -X- _ O
data -X- _ O
( -X- _ O
10 -X- _ O
studies -X- _ O
) -X- _ O
and -X- _ O
were -X- _ O
heterogeneous -X- _ O
in -X- _ O
terms -X- _ O
of -X- _ O
magnitude -X- _ O
and -X- _ O
direction -X- _ O
of -X- _ O
effect. -X- _ O
Included -X- _ O
studies -X- _ O
varied -X- _ O
in -X- _ O
terms -X- _ O
of -X- _ O
antigens -X- _ O
tested -X- _ O
, -X- _ O
methodology -X- _ O
used -X- _ O
to -X- _ O
measure -X- _ O
antibody -X- _ O
responses -X- _ O
, -X- _ O
and -X- _ O
epidemiological -X- _ O
setting. -X- _ O
Antibody -X- _ O
responses -X- _ O
to -X- _ O
pregnancy-specific -X- _ O
pRBC -X- _ O
and -X- _ O
VAR2CSA -X- _ O
antigens -X- _ O
, -X- _ O
measured -X- _ O
at -X- _ O
delivery -X- _ O
, -X- _ O
were -X- _ O
associated -X- _ O
with -X- _ O
placental -X- _ O
malaria -X- _ O
( -X- _ O
9 -X- _ O
studies -X- _ O
) -X- _ O
and -X- _ O
may -X- _ O
therefore -X- _ O
represent -X- _ O
markers -X- _ O
of -X- _ O
infection -X- _ O
, -X- _ O
rather -X- _ O
than -X- _ O
correlates -X- _ O
of -X- _ O
protection. -X- _ O
Antibody -X- _ O
responses -X- _ O
to -X- _ O
pregnancy-specific -X- _ O
pRBC -X- _ O
, -X- _ O
but -X- _ O
not -X- _ O
recombinant -X- _ O
VAR2CSA -X- _ O
antigens -X- _ O
, -X- _ O
were -X- _ O
associated -X- _ O
with -X- _ O
trends -X- _ O
towards -X- _ O
protection -X- _ O
from -X- _ O
low -X- _ O
birthweight -X- _ O
( -X- _ O
5 -X- _ O
studies -X- _ O
) -X- _ O
. -X- _ O
CONCLUSIONS -X- _ O
: -X- _ O
Whilst -X- _ B-Outcome
antibody -X- _ I-Outcome
responses -X- _ I-Outcome
to -X- _ I-Outcome
several -X- _ I-Outcome
antigens -X- _ I-Outcome
were -X- _ I-Outcome
positively -X- _ I-Outcome
associated -X- _ I-Outcome
with -X- _ I-Outcome
the -X- _ I-Outcome
presence -X- _ I-Outcome
of -X- _ I-Outcome
placental -X- _ I-Outcome
and -X- _ I-Outcome
peripheral -X- _ I-Outcome
infections -X- _ I-Outcome
, -X- _ I-Outcome
this -X- _ I-Outcome
review -X- _ I-Outcome
did -X- _ I-Outcome
not -X- _ I-Outcome
identify -X- _ I-Outcome
evidence -X- _ I-Outcome
that -X- _ I-Outcome
any -X- _ I-Outcome
specific -X- _ I-Outcome
antibody -X- _ I-Outcome
response -X- _ I-Outcome
is -X- _ I-Outcome
associated -X- _ I-Outcome
with -X- _ I-Outcome
protection -X- _ I-Outcome
from -X- _ I-Outcome
pregnancy-associated -X- _ I-Outcome
malaria -X- _ I-Outcome
across -X- _ I-Outcome
multiple -X- _ I-Outcome
populations. -X- _ I-Outcome
Further -X- _ O
prospective -X- _ O
cohort -X- _ O
studies -X- _ O
using -X- _ O
standardized -X- _ O
laboratory -X- _ O
methods -X- _ O
to -X- _ O
examine -X- _ O
responses -X- _ O
to -X- _ O
a -X- _ O
broad -X- _ O
range -X- _ O
of -X- _ O
antigens -X- _ O
in -X- _ O
different -X- _ O
epidemiological -X- _ O
settings -X- _ O
and -X- _ O
throughout -X- _ O
the -X- _ O
gestational -X- _ O
period -X- _ O
, -X- _ O
will -X- _ O
be -X- _ O
necessary -X- _ O
to -X- _ O
identify -X- _ O
and -X- _ O
prioritize -X- _ O
pregnancy-specific -X- _ O
P. -X- _ O
falciparum -X- _ O
antigens -X- _ O
to -X- _ O
advance -X- _ O
the -X- _ O
development -X- _ O
of -X- _ O
vaccines -X- _ O
and -X- _ O
serosurveillance -X- _ O
tools -X- _ O
targeting -X- _ O
pregnant -X- _ B-Patient
women -X- _ I-Patient
. -X- _ O

